FINCH THERAPEUTICS GROUP, INC. Financials Finch Therapeutics Group, Inc.
Equities
FNCH
US31773D2009
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.32 USD | +3.57% |
|
+3.57% | -35.73% |
| Mar. 25 | Finch Therapeutics Group, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| Mar. 12 | Top Premarket Decliners | MT |
Valuation
| Fiscal Period: December | 2021 | 2022 | 2023 |
|---|---|---|---|
| Capitalization 1 | 473.4 | 22.99 | 5.797 |
| Enterprise Value (EV) 1 | 345.9 | 4.311 | 10.8 |
| P/E ratio | -6.72 x | -0.2 x | -0.08 x |
| Yield | - | - | - |
| Capitalization / Revenue | 25.5 x | 26.7 x | 54.2 x |
| EV / Revenue | 18.7 x | 5.01 x | 101 x |
| EV / EBITDA | -6 x | -0.05 x | -0.33 x |
| EV / FCF | -7,287,090 x | -95,485 x | -451,658 x |
| FCF Yield | -0% | -0% | -0% |
| Price to Book | 2.34 x | 0.24 x | 0.25 x |
| Nbr of stocks (in thousands) | 1,583 | 1,597 | 1,606 |
| Reference price 2 | 299.1 | 14.40 | 3.610 |
| Announcement Date | 3/31/22 | 3/23/23 | 3/25/24 |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| Net sales 1 | 10.15 | 7.719 | 18.53 | 0.861 | 0.107 |
| EBITDA 1 | -20.66 | -38.65 | -57.68 | -89.61 | -32.48 |
| EBIT 1 | -21.14 | -39.44 | -59.98 | -95.12 | -34 |
| Operating Margin | -208.21% | -510.9% | -323.68% | -11,047.62% | -31,777.57% |
| Earnings before Tax (EBT) 1 | -20.75 | -39.34 | -58.16 | -114.6 | -78.22 |
| Net income 1 | -20.75 | -39.34 | -58.16 | -114.6 | -74.75 |
| Net margin | -204.39% | -509.66% | -313.84% | -13,315.45% | -69,863.55% |
| EPS 2 | -85.34 | -144.9 | -44.51 | -72.12 | -46.59 |
| Free Cash Flow | - | -19.28 | -47.47 | -45.15 | -23.91 |
| FCF margin | - | -249.78% | -256.15% | -5,243.55% | -22,345.09% |
| FCF Conversion (EBITDA) | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - |
| Announcement Date | 12/28/20 | 2/26/21 | 3/31/22 | 3/23/23 | 3/25/24 |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | 0.806 | - | 0.361 | 0.138 | 0.008 | 0.107 | - |
| EBITDA | - | - | - | -20.36 | - | - | - | - |
| EBIT 1 | - | -19.06 | - | -21.73 | -21.3 | -27.51 | -18.1 | -9.08 |
| Operating Margin | - | -2,365.01% | - | -6,018.28% | -15,438.41% | -343,862.5% | -16,914.02% | - |
| Earnings before Tax (EBT) 1 | - | - | - | -22.7 | -40.37 | -27.01 | -67.4 | -6.95 |
| Net income 1 | - | -19.06 | -24.57 | -22.7 | -40.37 | -27.01 | -63.94 | -6.95 |
| Net margin | - | -2,364.14% | - | -6,288.09% | -29,254.35% | -337,600% | -59,756.07% | - |
| EPS 2 | -6.300 | -12.00 | -15.60 | -14.40 | -25.50 | -16.80 | -39.90 | -4.330 |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 11/10/21 | 3/31/22 | 5/16/22 | 8/11/22 | 11/10/22 | 3/23/23 | 5/10/23 | 8/10/23 |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | 5 |
| Net Cash position 1 | 42.1 | 97.9 | 127 | 18.7 | - |
| Leverage (Debt/EBITDA) | - | - | - | - | -0.154 x |
| Free Cash Flow | - | -19.3 | -47.5 | -45.1 | -23.9 |
| ROE (net income / shareholders' equity) | - | -35.6% | -34.3% | -77% | -126% |
| ROA (Net income/ Total Assets) | - | -18.3% | -19.2% | -30.6% | -19.5% |
| Assets 1 | - | 214.6 | 303.1 | 374.4 | 384 |
| Book Value Per Share 2 | -230.0 | -342.0 | 128.0 | 59.80 | 14.30 |
| Cash Flow per Share 2 | 163.0 | 356.0 | 84.30 | 44.30 | 15.60 |
| Capex 1 | 1.01 | 2.63 | 16 | 2.18 | - |
| Capex / Sales | 9.9% | 34.11% | 86.25% | 253.43% | - |
| Announcement Date | 12/28/20 | 2/26/21 | 3/31/22 | 3/23/23 | 3/25/24 |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| -35.73% | 3.73M | |
| +1.51% | 42.75B | |
| +49.22% | 41.61B | |
| +8.57% | 41.34B | |
| -12.36% | 26.59B | |
| +8.92% | 25.49B | |
| -25.13% | 18.12B | |
| +29.17% | 12.24B | |
| -3.12% | 11.76B | |
| +6.35% | 11B |
- Stock Market
- Equities
- FNCH Stock
- Financials Finch Therapeutics Group, Inc.
